Asgard Therapeutics' study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108

Asgard Therapeutics United Kingdom United States of America Sweden

Study of Asgard's new cancer immunotherapy modality demonstrates potent anti-tumor effects by turning tumor cells against themselvesNew data "paves the way for first-in-human trials" of lead program AT-108, which is undergoing CMC development for GMP manufacturingAT-108 is an off-the-shelf gene therapy that induces an immune response tailored against each unique patient's cancerView original content:https://www.prnewswire.co.uk/news-releases/asgard-therapeutics-study-published-in-science-showing-proof-of-concept-and-strong-anti-tumor-responses-via-in-vivo-cell-reprogramming-with-lead-program-at-108-302239512.html